A Phase 3 trial of an experimental drug for relapsing-remitting multiple sclerosis, laquinimod, has failed to meet its primary endpoint which was to show an improvement in the time to confirmed disease progression. ---Subscribe to MedNous to access this article--- Clinical Research Company News
